Product Information
- INCB 028050 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile LY 3009104
Baricitinib is a Janus kinase inhibitor (JAK) currently used as monotherapy in the treatment of rheumatoid arthritis. Barictinib is also recommened for the treatment of atopic dermatitis and systemic lupus erythematosus. In mice interestingly, the administration of baricitinib reduced the inflammatory effects induced by a high-sugar diet on the metabolism.
Baricitinib is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.
Chemical properties
Technical inquiry about: Baricitinib - Bio-X ™
Please use instead the cart to request a quotation or an order
